Stericycle Inc. (SRCL) Stock Price Up 0.9%
Stericycle Inc. (NASDAQ:SRCL) shares rose 0.9% on Wednesday . The company traded as high as $85.93 and last traded at $85.57, with a volume of 738,035 shares trading hands. The stock had previously closed at $84.84.
SRCL has been the topic of a number of research reports. Jefferies Group restated a “buy” rating and issued a $140.00 price objective on shares of Stericycle in a report on Tuesday, May 17th. Zacks Investment Research upgraded Stericycle from a “hold” rating to a “buy” rating and set a $119.00 price objective on the stock in a report on Thursday, July 21st. Wellington Shields lowered Stericycle from an “accumulate” rating to a “hold” rating in a report on Friday, July 29th. Imperial Capital decreased their price objective on Stericycle from $100.00 to $95.00 and set an “in-line” rating on the stock in a report on Thursday, May 26th. Finally, Wedbush decreased their price objective on Stericycle from $112.00 to $100.00 and set a “neutral” rating on the stock in a report on Monday, May 9th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the company. Stericycle has a consensus rating of “Hold” and an average target price of $118.15.
The stock has a 50 day moving average price of $93.76 and a 200 day moving average price of $105.75. The firm has a market capitalization of $7.31 billion and a PE ratio of 30.26.
Stericycle (NASDAQ:SRCL) last posted its earnings results on Thursday, July 28th. The company reported $1.18 EPS for the quarter, hitting the Zacks’ consensus estimate of $1.18. The firm had revenue of $891.60 million for the quarter, compared to analysts’ expectations of $910.29 million. The firm’s revenue for the quarter was up 24.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.14 earnings per share. On average, analysts predict that Stericycle Inc. will post $4.69 earnings per share for the current fiscal year.
In related news, Director Mark C. Miller sold 24,665 shares of the company’s stock in a transaction on Friday, July 1st. The stock was sold at an average price of $104.55, for a total value of $2,578,725.75. Following the completion of the transaction, the director now directly owns 229,449 shares in the company, valued at $23,988,892.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Rodney F. Dammeyer sold 10,188 shares of the company’s stock in a transaction on Wednesday, August 17th. The shares were sold at an average price of $85.50, for a total value of $871,074.00. Following the completion of the transaction, the director now owns 10,188 shares of the company’s stock, valued at $871,074. The disclosure for this sale can be found here.
A number of institutional investors have added to or reduced their stakes in SRCL. RS Investment Management Co. LLC acquired a new position in Stericycle during the fourth quarter valued at approximately $9,539,000. KBC Group NV raised its stake in shares of Stericycle by 563.2% in the fourth quarter. KBC Group NV now owns 27,117 shares of the company’s stock valued at $3,270,000 after buying an additional 23,028 shares in the last quarter. Finally, US Bancorp DE raised its stake in shares of Stericycle by 33.2% in the fourth quarter. US Bancorp DE now owns 229,894 shares of the company’s stock valued at $27,725,000 after buying an additional 57,322 shares in the last quarter.
Stericycle, Inc is a business-to-business services provider with a focus on regulated and compliance solutions for healthcare, retail and commercial businesses. The Company’s solutions include the collection and processing of specialized waste for disposal, the collection of personal and confidential information for secure destruction, and a range of training, consulting, recall/return, communication and compliance services.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.